Echo Therapeutics, Inc. announced earnings results for the second quarter ended June 30, 2016. For the quarter, the company reported net loss of $9.4 million or $0.82 per share compared to $10.8 million or $0.97 per share for the same period in 2015. Operating loss was $1.5 million compared to $12.3 million for the second quarter of 2015. The 2015 second quarter operating loss was significantly impacted by a one-time $9.6 million impairment charge for the company's Azone intangibles. Research and development (R&D) expenses were $0.7 million for both the second quarter of 2016 and 2015.  Selling, general and administrative (S,G&A) expenses were $0.8 million during the second quarter of 2016 compared to $1.5 million during the second quarter of 2015. The decrease in S,G&A expenses was primarily due to a decline in legal fees.